Atenolol -SIL NDSRI
References
FAQ's
References
- Barrett, Arthur M.; Hull, Roy; Le Count, David J.; Squire, Christopher J.; Carter, John, Alkanolamine derivatives, GB1285038A, Aug 9, 1972, Imperial Chemical Industries Ltd., United Kingdom (https://www.lens.org/lens/search/patent/list?q=GB1285038)
- Scales, Bryan; Copsey, Paul B, Gas chromatographic determination of atenolol in biological samples, Journal of Pharmacy and Pharmacology, Volume: 27, Issue: 6, Pages: 430-3, 1975 DOI: (1111/j.2042-7158.1975.tb09473.x)
- Weddle, Orville H.; Amick, Edwin N.; Mason, William D., Rapid determination of atenolol in human plasma and urine by high-pressure liquid chromatography, Journal of Pharmaceutical Sciences, Volume: 67, Issue: 7, Pages: 1033-5, 1978 DOI: (10.1002/jps.2600670748)
Frequently Asked Questions
2.How do we analyze Atenolol impurities in the drug substance?
HPLC method analyzes Atenolol impurities in the drug substance.
3.How do we control Nitrosamine Impurities in Atenolol?
During process development, manufacturers can avoid reactions that produce nitrosamines, use amide solvents, and monitor any cross-contamination of materials. Further, the control strategy should have specification limits to detect nitrosamine levels in Atenolol.
4.What is the source of Atenolol impurities?
The source of Atenolol impurities includes unreacted starting materials, by-products, intermediates, solvents, and reagents.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.